AnaptysBio, Inc. - Common Stock (NQ:ANAB)

49.50 -18.01 (-26.68%)

Streaming Delayed Price Updated: 1:56 PM EDT, Apr 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AnaptysBio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

The Past Week's Notable Insider Buys: Amphenol, Aldeyra, Werewolf Therapeutics, And More ↗

May 08, 2021

Insider buying can be an encouraging signal for investors, especially when markets are near all-time highs. Some insiders have taken advantage of initial public offerings. A few chief executive...

Via Talk Markets

The Past Week's Notable Insider Buys: Amphenol, Aldeyra, Werewolf Therapeutics And More ↗

May 08, 2021

Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs. Once again, some insiders have taken advantage of initial...

Via Benzinga

Last Week's Notable Insider Buys: Beacon Roofing, Chipotle, IPOs, Latham And More ↗

May 02, 2021

Here are some of the most noteworthy insider purchases that were reported in the past week.

Via Talk Markets

Last Week's Notable Insider Buys: Beacon Roofing, Chipotle, IPOs, Latham And More ↗

May 02, 2021

Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs. Once again, some insiders took advantage of recent public...

Via Benzinga

The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline ↗

August 18, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

AnaptysBio-Generated Antibody Scores Second FDA Approval For Solid Tumor Indication ↗

August 18, 2021

The FDA has approved a second indication for GlaxoSmithKline plc's (NYSE: GSK) Jemperli (dostarlimab-gxly). The approval comes for adult patients with...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 21, 2021 ↗

May 21, 2021

Upgrades According to JP Morgan, the prior rating for ResMed Inc (NYSE:RMD) was changed from Neutral to Overweight. For the third quarter, ResMed had an EPS of $1.30,...

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.